Ipilimumab plus nivolumab for advanced melanoma
Mené en France et aux Etats-Unis sur 142 patients atteints d'un mélanome de stade avancé, cet essai randomisé de phase II évalue l'efficacité, du point de vue du taux de réponse objective et de la survie globale, et la toxicité d'un traitement de première ligne combinant nivolumab et ipilimumab
Blockade of immune checkpoints has revolutionised cancer immunotherapy in the past few years. Ipilimumab, which blocks CTLA-4, was the first immune checkpoint inhibitor to substantially improve the overall survival of patients with metastatic melanoma. Despite only about 10% of patients achieving an objective response, long-term survival could be achieved, with 26% of patients living for longer than 3 years after first-line treatment. For the PD-1 antibodies pembrolizumab and nivolumab, responses were seen in between 30% and 40% of participants and 2-year overall survival was roughly 60%.
The Lancet Oncology , commentaire, 2015